Wang Ping, Yang Dawei, Zhang Honglian, Wei Xuyu, Ma Tianle, Cheng Zule, Hong Qunying, Hu Jie, Zhuo Hanjing, Song Yuanlin, Jia Chunping, Jing Fengxiang, Jin Qinghui, Bai Chunxue, Mao Hongju, Zhao Jianlong
State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Science, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Clin Lung Cancer. 2015 Jul;16(4):313-9.e1. doi: 10.1016/j.cllc.2014.12.006. Epub 2014 Dec 24.
The objective of the study was to develop a panel of microRNAs (miRNAs) as highly sensitive and specific biomarkers for lung cancer early detection.
The study contained 2 phases: first, preliminary marker selection based on previous reports on the serum of 24 early stage lung cancer patients and 24 healthy control subjects by TaqMan probe-based real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR); and second, validation of miRNA markers on 94 early stage lung cancer, 48 stage III to IV lung cancer, and 111 healthy control serum samples.
A total of 3 miRNAs (miR-125a-5p, miR-25, and miR-126) were selected for further analysis in this study. The combination of the 3 miRNAs could produce 0.936 area under the receiver operating characteristic curve value in distinguishing early stage lung cancer patients from control subjects with 87.5% sensitivity and 87.5% specificity, respectively. The diagnostic value of the miRNA panel in an independent set of lung cancer patients confirmed the sensitivity and specificity.
The results demonstrated that the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
本研究的目的是开发一组微小RNA（miRNA）作为肺癌早期检测的高灵敏度和特异性生物标志物。
本研究包括两个阶段：第一，基于先前对24例早期肺癌患者和24例健康对照者血清的报道，通过基于TaqMan探针的实时逆转录定量聚合酶链反应（RT-qPCR）进行初步标志物筛选；第二，在94例早期肺癌、48例III至IV期肺癌和111例健康对照血清样本上对miRNA标志物进行验证。
本研究共选择了3种miRNA（miR-125a-5p、miR-25和miR-126）进行进一步分析。这3种miRNA的组合在区分早期肺癌患者与对照者时，受试者工作特征曲线下面积值为0.936，灵敏度和特异性分别为87.5%。miRNA检测组合在一组独立的肺癌患者中的诊断价值证实了其灵敏度和特异性。
结果表明，miRNA生物标志物组合具有肺癌早期检测的潜力。
